BIOLINERX
Careers | Contact Us
search

Press Releases
February 21, 2012
Data showing reduction of gluten toxicity published in leading medical journal Gastroenterology
February 6, 2012

Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030

Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions

December 13, 2011
Framework agreement initiated with three Compugen-discovered peptides mutually selected for further development by BioLineRx
251-260  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next